References
- Josefsberg JO, Buckland B. Vaccine process technology. Biotechnol Bioeng 2012;109:1443-60; http://dx.doi.org/10.1002/bit.24493.
- Cox MM, Hashimoto Y. A fast track influenza virus vaccine produced in insect cells. J Invertebr Pathol 2011;107(Suppl.):S31-4; PMID:21784229; http://dx.doi.org/10.1016/j.jip.2011.05.003.
- Buckland Barry, Boulanger Robert, Fino M, Srivastava I, Holtz K, Khramtsov N, McPherson C, Meghrous J, Kubera P, Cox MM. Technology transfer and scale-up of the Flublok® recombinant hemagglutinin (HA) influenza vaccine manufacturing process Vaccine 2014; 32 5496-5502; PMID:25131727; http://dx.doi.org/10.1016/j.vaccine.2014.07.074.
- Fedson DS, Dunnill P. New approaches to confronting an imminent influenza pandemic. Permanente J 2007; 11:63-9.
- Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, Fonseca K, Winter AL, Gubbay JB, Krajden M, et al. Low 2012–13 Influenza Effectiveness Associated with Mutation in the Egg Adapted H3N2 vaccine Strain Not Antigenic drift in circulating Viruses. 2014. PLOSone 2014; 9(3):e92153; DOI : 10.1371/journal.pone.0092153.
- Butler D. Mutations explain poor showing of 2012 flu vaccine. Nature News; http://dx.doi.org/10.1038/nature.2014.14940
- Treanor John J, El Sahly, Hana King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: A randomized, placebo-controlled trial. Vaccine 2011; 29: 7733-7739; PMID:21835220; http://dx.doi.org/10.1016/j.vaccine.2011.07.128.
- Friede M, Palkonyay L, Alfonso C, Pervikov Y, Torelli G, Wood D, et al. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Vaccine 2011;29(Suppl. One):A2-7 [Review]; PMID:21684422; http://dx.doi.org/10.1016/j.vaccine.2011.02.079.